IL195161A0 - Pharmaceutical compositions of ropinirole and methods of use thereof - Google Patents

Pharmaceutical compositions of ropinirole and methods of use thereof

Info

Publication number
IL195161A0
IL195161A0 IL195161A IL19516108A IL195161A0 IL 195161 A0 IL195161 A0 IL 195161A0 IL 195161 A IL195161 A IL 195161A IL 19516108 A IL19516108 A IL 19516108A IL 195161 A0 IL195161 A0 IL 195161A0
Authority
IL
Israel
Prior art keywords
ropinirole
methods
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL195161A
Other languages
English (en)
Original Assignee
Jazz Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Inc filed Critical Jazz Pharmaceuticals Inc
Publication of IL195161A0 publication Critical patent/IL195161A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL195161A 2006-06-29 2008-11-06 Pharmaceutical compositions of ropinirole and methods of use thereof IL195161A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81725906P 2006-06-29 2006-06-29
PCT/US2007/014821 WO2008005240A2 (en) 2006-06-29 2007-06-26 Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof

Publications (1)

Publication Number Publication Date
IL195161A0 true IL195161A0 (en) 2009-08-03

Family

ID=38895093

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195161A IL195161A0 (en) 2006-06-29 2008-11-06 Pharmaceutical compositions of ropinirole and methods of use thereof

Country Status (17)

Country Link
US (1) US20080004329A1 (enExample)
EP (1) EP2032125A2 (enExample)
JP (1) JP2009542657A (enExample)
KR (1) KR20090031598A (enExample)
CN (1) CN101478952A (enExample)
AR (1) AR063201A1 (enExample)
AU (1) AU2007269896A1 (enExample)
BR (1) BRPI0713801A2 (enExample)
CA (1) CA2654383A1 (enExample)
IL (1) IL195161A0 (enExample)
MX (1) MX2008015083A (enExample)
NO (1) NO20085158L (enExample)
NZ (1) NZ572481A (enExample)
PE (1) PE20080374A1 (enExample)
TW (1) TW200815045A (enExample)
UY (1) UY30442A1 (enExample)
WO (1) WO2008005240A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
KR20120024562A (ko) * 2009-04-24 2012-03-14 히사미쓰 세이야꾸 가부시키가이샤 첩부제 수용 포장 백, 및 첩부제의 보존 방법
MX378797B (es) * 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
CN103561737A (zh) * 2011-05-31 2014-02-05 久光制药株式会社 含有罗匹尼罗的贴附剂及其包装体
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP3275466A1 (en) 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
JP6234936B2 (ja) * 2012-11-30 2017-11-22 帝國製薬株式会社 ロピニロール含有貼付剤
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
US9463889B2 (en) * 2013-10-25 2016-10-11 Medtronic, Inc. Prefilled reservoir apparatus for ambulatory infusion device
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
US10716763B2 (en) 2015-04-15 2020-07-21 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch containing ropinirole
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2017301928B2 (en) * 2016-07-27 2023-04-06 Corium, LLC. Donepezil transdermal delivery system
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN116763842B (zh) * 2023-07-11 2025-03-04 海南职业技术学院 一种胆木浸膏凝胶剂及其制备工艺

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
DE3522550A1 (de) * 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6321105B1 (en) * 1998-04-08 2001-11-20 Bracco S.P.A. Method for diagnosing neurological, neurodegenerative and psychiatric diseases by magnetic resonance imaging using contrast agents with high magnetic susceptibility and extended plasma half life
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
PT1616561E (pt) * 1999-12-28 2008-07-09 Ajinomoto Kk Preparação antidiabética para administração oral
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
CA2407031A1 (en) * 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6770297B1 (en) * 2000-05-26 2004-08-03 Unitech Pharmaceuticals, Inc. Controlled release delivery system of solid dosage form
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002246490A1 (en) * 2000-10-12 2002-07-30 Pharmacia And Upjohn Company Method of treating parkinson's disease
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6656882B2 (en) * 2001-02-28 2003-12-02 Oms Investments, Inc. Controlled release products and processes for the preparation thereof
WO2002085335A1 (en) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US6833478B2 (en) * 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
US20040157910A1 (en) * 2003-02-10 2004-08-12 Smithkline Beecham Corporation Method of treatment or prophylaxis
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US20070048360A1 (en) * 2005-08-23 2007-03-01 R Carrara Dario N Pharmaceutical compositions with melting point depressant agents and method of making same

Also Published As

Publication number Publication date
PE20080374A1 (es) 2008-06-11
WO2008005240A3 (en) 2008-05-08
BRPI0713801A2 (pt) 2012-11-06
AU2007269896A1 (en) 2008-01-10
NZ572481A (en) 2011-03-31
CN101478952A (zh) 2009-07-08
CA2654383A1 (en) 2008-01-10
MX2008015083A (es) 2008-12-10
US20080004329A1 (en) 2008-01-03
UY30442A1 (es) 2008-01-31
EP2032125A2 (en) 2009-03-11
AR063201A1 (es) 2009-01-14
KR20090031598A (ko) 2009-03-26
JP2009542657A (ja) 2009-12-03
TW200815045A (en) 2008-04-01
WO2008005240A2 (en) 2008-01-10
NO20085158L (no) 2009-01-15

Similar Documents

Publication Publication Date Title
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
EP2054063A4 (en) 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE
IL192990A0 (en) Methods and compositions of targeted drug development
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
IL207724A0 (en) Cns pharmaceutical compositions and methods of use
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
PL2069467T3 (pl) Kompozycje wydzielające i sposoby stosowania
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL192564A0 (en) Composition and method of use thereof
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes